Navigation Links
Seven Abstracts Featuring Exelixis Compounds Accepted for Presentation at 2008 ASCO Annual Meeting
Date:3/31/2008

Two oral presentations, two poster discussion presentations, three poster

presentations

SOUTH SAN FRANCISCO, Calif., March 31 /PRNewswire-FirstCall/ -- Exelixis, Inc. (Nasdaq: EXEL) announced today that data from clinical trials of the company's investigational compounds XL647, XL184, XL765 and XL880 will be presented at the 2008 American Society of Clinical Oncology (ASCO) Annual Meeting, which will be held from May 30 to June 3, 2008 in Chicago, Illinois. The clinical trial data will be described in two oral presentations (XL184 and XL765), two poster presentations and discussions (XL647), and three poster presentations (XL647 and XL880).

Oral Presentations

-- XL184 (RET, MET, VEGFR2). Data from a phase 1 trial of XL184 in

patients with advanced malignancies, including medullary thyroid

cancer, will be presented on Sunday, June 1, 2008, starting at 10 a.m.

local time (Abstract #3522).

-- XL765 (PI3K, mTOR). Data from a phase 1 trial of XL765 in patients

with advanced solid tumors will be presented on Saturday, May 31,

2008, starting at 1:15 p.m. local time (Abstract #3510).

Poster Presentations and Discussions

-- XL647 (EGFR, HER2, VEGFR2). Data from a phase 2 trial of XL647 in

NSCLC patients with acquired resistance to EGFR tyrosine kinase

inhibitors will be presented on Monday, June 2, 2008, during the 8

a.m.-noon session (Abstract #8028).

-- XL647 (EGFR, HER2, VEGFR2). Data from a phase 1 trial of XL647 dosed

daily in patients with advanced solid malignancies will be presented

on Saturday, May 31, 2008, during the 8 a.m.-noon session (Abstract

#3528).

Poster Presentations

-- XL647 (EGFR, HER2, VEGFR2). Data from a phase 2 trial of XL647 in

clinically selected NSCLC patients enriched for the presence of EGFR

mutations will be presented on Sunday, June 1, 2008, during the 2-6

p.m. session (Abstract #8053).

-- XL880* (MET, VEGFR2). Data from a phase 2 trial of XL880 in patients

with papillary renal cell carcinoma will be presented on Saturday, May

31, 2008, during the 8 a.m.-noon session (Abstract #5103).

-- XL880* (MET, VEGFR2). Data from a phase 2 trial of XL880 in MET

amplified, poorly differentiated gastric cancer will be presented on

Monday, June 2, 2008, during the 8 a.m.-2 p.m. session (Abstract

#4572).

* XL880 was selected by GlaxoSmithKline in December 2007 for further

development and commercialization.

About Exelixis

Exelixis, Inc. is a development-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer and other serious diseases. The company is leveraging its fully integrated drug discovery platform to fuel the growth of its development pipeline, which is primarily focused on cancer. Currently, Exelixis' broad product pipeline includes investigational compounds in phase 2 and phase 1 clinical development. Exelixis has established strategic corporate alliances with major pharmaceutical and biotechnology companies, including GlaxoSmithKline, Bristol-Myers Squibb Company, Genentech, Wyeth Pharmaceuticals and Daiichi-Sankyo. For more information, please visit the company's web site at http://www.exelixis.com.

Exelixis and the Exelixis logo are registered U.S. trademarks.


'/>"/>
SOURCE Exelixis, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Covance Reports Full-Year 2007 Revenue Growth Of 15.4% and Seventh Consecutive Year of EPS Growth in Excess of 20%
2. Seven Summits Research Releases Alerts on XOM, MER, DRYS, CSC, and PDLI
3. Pharmacopeia To Present at BMO Capital Markets Seventh Annual Focus on Healthcare Conference
4. MedImmune Announces Seven Key Promotions and New Hires
5. SemBioSys to present insulin data at the Seventh Annual Diabetes Technology Meeting
6. ThromboGenics - Business Update and Interim Results for the Seven Month Period Ending 30 June 2007
7. ARIUS announces five abstracts selected for presentation at 2008 AACR Annual Meeting
8. Jarrow Formulas Launches New Products Featuring BioCell Collagen II(R)
9. Pediatric Asthma Programs Featuring PARI Pharmas eFlow Acquired by AstraZeneca
10. Vital Images Releases Next Generation Enterprise-Wide Solutions Featuring Vitrea(R) 4.0 and ViTALConnect(R) 4.1
11. Option to Develop Exelixis Compound Exercised By Genentech
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/16/2017)... Jan. 16, 2017   Valentin A. Pavlov, PhD ... , president and CEO of The Feinstein Institute ... analysis of how the nervous system regulates the immune ... bioelectronic medicine devices to treat disease and ... Neuroscience . The paper examines various studies ...
(Date:1/16/2017)... , Jan. 16, 2017  Eurofins Genomics today ... will allow more customers to receive their primers in ... or compromise in quality found with other providers. Express ... United States at no additional fee. ... routine genetic studies, including DNA sequencing, genotyping, site-directed mutagenesis, ...
(Date:1/14/2017)... 13, 2017  The Alliance for Safe Biologic Medicines ... FDA final guidance on biologic naming: ... in emphasizing the importance of distinct naming for all ... the benefits biosimilars will bring to patients, including new ... the portion of the Guidance dealing with suffix design ...
(Date:1/13/2017)... and Markets has announced the addition of the "Global Biopolymers Market ... ... 16.83% during the period 2017-2021. The report covers the ... 2017-2021. To calculate the market size, the report considers the revenue generated ... a a discussion of the key vendors operating in this market. ...
Breaking Biology Technology:
(Date:12/15/2016)... Calif. , Dec. 15, 2016   WaferGen ... publicly held genomics technology company, announced today that on ... Listing Qualifications Department of The Nasdaq Stock Market LLC ... closing bid price of WaferGen,s common stock had been ... Accordingly, WaferGen has regained compliance with Listing Rule 5550(a)(2) ...
(Date:12/15/2016)... 2016  There is much more to innovative access ... engine. Continental will demonstrate the intelligence of today,s solutions ... . Through the combination of the keyless entry and ... elements, the international technology company is opening up new ... "The integration of biometric elements brings our ...
(Date:12/8/2016)... 2016 Market Research Future published a half cooked research ... Biometric Security and Service Market is expected to grow over the ... Market Highlights: ... Mobile Biometric Security and Service Market ... need of authentication and security from unwanted cyber threats. The increasing ...
Breaking Biology News(10 mins):